Capital International Inc. CA Sells 18,184 Shares of BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Inc. CA trimmed its holdings in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 5.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 307,660 shares of the company’s stock after selling 18,184 shares during the quarter. Capital International Inc. CA owned 0.28% of BeOne Medicines worth $93,470,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the business. Leonteq Securities AG bought a new position in shares of BeOne Medicines during the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the second quarter worth $35,000. CWM LLC lifted its holdings in shares of BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after buying an additional 39 shares in the last quarter. Finally, EverSource Wealth Advisors LLC acquired a new position in BeOne Medicines in the second quarter valued at about $68,000. 48.55% of the stock is owned by institutional investors.

Insider Transactions at BeOne Medicines

In other news, SVP Chan Henry Lee sold 332 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04. Following the sale, the senior vice president directly owned 101 shares in the company, valued at approximately $31,382.72. The trade was a 76.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Margaret Dugan sold 212 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.60, for a total value of $65,635.20. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 1,641 shares of company stock valued at $505,791. 6.19% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Royal Bank Of Canada boosted their target price on BeOne Medicines from $425.00 to $436.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and lowered their target price for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Wolfe Research assumed coverage on BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Barclays boosted their target price on BeOne Medicines from $405.00 to $409.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $270.10 on Friday. The stock has a market cap of $29.64 billion, a P/E ratio of 60.43 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock’s 50-day moving average is $301.86 and its 200-day moving average is $317.87. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Equities research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.